A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disea… (NCT07416344) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
China14,980 participantsStarted 2026-03-01
Plain-language summary
The CARDIAC trial is a prospective, parallel, open-label cluster randomized trial that aims to determine the effectiveness of a coronary computed tomography angiography (CTA)-guided intensive intervention strategy, as compared with standard care, on reducing the incidence of major adverse events (MACE) at 18 months among high-risk cardiovascular populations in rural China. An extended observational follow-up at 36 months will be conducted to further evaluate the effect on long-term clinical outcomes.
Who can participate
Age range40 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Administrative villages
✓. The village has no plans to merge with other villages within 3 years
✓. The village is at least 2 kilometers away from other participating villages
✓. The village has a sufficient number of study participants
✓. The village is able to cooperate with the implementation of the study
✓. Men or women aged between 40 and 75 years
✓. Live stably in the province where the study is conducted and no intention to migrate within next 3 years
✓. Not participating in other clinical trials
Exclusion criteria
✕. Unwillingness or inability to undergo coronary CTA examination (e.g., previous history of severe contrast allergy, claustrophobia, or inability to cooperate with scanning and breath-holding for physical reasons in study participants)
✕. Typical angina symptoms, known coronary artery disease, or other major atherosclerotic cardiovascular disease
✕. Known cerebrovascular disease (e.g., cerebral hemorrhage, cerebral infarction, etc. )
✕. Prior invasive or non-invasive coronary angiography within the last 5 years
. Known familial hypercholesterolemia or other inherited disorders of lipid metabolism requiring lipid-lowering therapy
✕. Presence of active bleeding or diseases with a very high risk of bleeding (e.g., active peptic ulcer disease, gastrointestinal pathologies with increased risk of bleeding, hematologic disorders with increased risk of bleeding, etc.)
✕. End-stage diseases such as cirrhosis decompensation, with life expectancy \<3 years